Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a retrospective and what the future may hold.
Cardiovascular complications dominate the landscape of chronic kidney diseases (CKD). Endothelial cell dysfunction (ECD) is a well-known culprit of cardiovascular morbidity and it develops in CKD with remarkable frequency. This brief overview of ECD in CKD scans two decades of studies performed in my laboratory, from genetic analyses to proteomic and metabolomics screens. I provide a detailed description of findings related to the premature senescence of endothelial cells, cell transition from the endothelial to mesenchymal phenotype, and stages of development of ECD. Clinical utility of some of these findings is illustrated with data on laser-Doppler flowmetry and imaging in patients with CKD. Some currently available and emerging therapeutic options for the management of ECD are briefly presented.
Departments of Medicine, Pharmacology and Physiology, Renal Research Institute, New York Medical College, Valhalla, NY, USA ; Departments of Pharmacology and Physiology, Pharmacology and Physiology, Renal Research Institute, New York Medical College, Valhalla, NY, USA.
Michael S
MS
Goligorsky
Endothelial-to-mesenchymal  transition; Metabolomics; Premature senescence proteomics; Stress-induced